ZURICH, Oct 10 (Reuters) - Swiss medical technology

company Ypsomed said on Friday it will establish its

first manufacturing facility in the United States with an

initial $200 million investment in the town of Holly Springs,

North Carolina.

Ypsomed, a maker of self-injection systems, said it plans to

create about 100 new jobs and wants to roughly double that

number in the coming years as demand rises. The plant is due to

begin supplying the U.S. market from the end of 2027.

The investment comes as Swiss companies grapple with the

challenges posed by the U.S. government's trade policies, which

have imposed 39% tariffs on Switzerland.

Earlier this year, Ypsomed opened its first manufacturing

plant in China. The firm is also expanding its operations in the

northeastern German city of Schwerin, where it is investing

several hundred million Swiss francs.

Ypsomed is also increasing domestic production capacity,

including a 200 million franc ($248 million) outlay at its

facility in Solothurn in northwest Switzerland.

($1 = 0.8056 Swiss francs)

(Reporting by Dave Graham, editing by Thomas Seythal)